{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T22:21:13Z","timestamp":1767651673554},"reference-count":163,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2021,3,12]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>Proliferative diabetic retinopathy and diabetic macular edema can be a potentially sightthreatening disease if not treated correctly. It is directly correlated to the duration of diabetes and how well managed the patients' diabetes is. In the last 15 years, the treatment of diabetic eye disease has taken a quantum leap in methodology due to the group of biological agents named antivascular endothelial growth factor (anti-VEGF). The introduction of the first biological agent has revolutionized the treatment, not only in diabetic eye disease but also across most inflammatory eye diseases, causing leakage of fluid from the blood vessels i.e., in age-related macular degeneration. The availability of these biological agents, despite their considerable costs, have significantly improved the outcomes measured in visual acuity compared to more traditional treatments of diabetic retinopathy in the form of sole laser treatment and glycemic control. The agents demonstrate a favorable safety profile, but if the rarest and most severe side effects occur, there is a potential total loss of vision.<\/jats:p><\/jats:sec><jats:sec><jats:title\/><jats:p>This review aims to make an overview of the current pharmaceutical therapeutic options in the treatment of diabetic macular edema. This includes laser therapy, intravitreal steroids, and a primary focus on intravitreal antivascular endothelial growth factors.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1574886315666200902154322","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T16:54:47Z","timestamp":1599152087000},"page":"17-31","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Biologic Therapy and Treatment Options in Diabetic Retinopathy with Diabetic Macular Edema"],"prefix":"10.2174","volume":"16","author":[{"given":"Tobias P. H.","family":"Nissen","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital Hobrovej 18-22, 9000Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Vorum","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aalborg University Hospital Hobrovej 18-22, 9000Aalborg, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristian","family":"Aasbjerg","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Aarhus University Hospital, Palle Juul-Jensens Blvd. 161, 8200Aarhus, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1016\/j.ajpath.2012.07.022","volume":"181","author":"Korsgren S.","year":"2012","unstructured":"Korsgren S.; Molin Y.; Salmela K.; Lundgren T.; Melhus A.; Korsgren O.; On the etiology of type 1 diabetes: A new animal model signifying a decisive role for bacteria eliciting an adverse innate immunity response. Am J Pathol 2012,181(5),1735-1748","journal-title":"Am J Pathol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1152\/physrev.00003.2010","volume":"91","author":"van Belle T.L.","year":"2011","unstructured":"van Belle T.L.; Coppieters K.T.; von Herrath M.G.; Type 1 diabetes: Etiology, immunology, and therapeutic strategies. Physiol Rev 2011,91(1),79-118","journal-title":"Physiol Rev"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.immuni.2010.04.001","author":"Todd J.A.","year":"2010","unstructured":"Todd J.A.; Vol 32, Immunity 2010,457-67","journal-title":"Vol 32, Immunity"},{"key":"ref=4","first-page":"71","author":"Ackland P.","year":"2018","unstructured":"Ackland P.; Resnikoff S.; Bourne R.; Vol 30, Community Eye Health Journal 2018,71-3","journal-title":"Vol 30, Community Eye Health Journal"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s40662-015-0026-2","volume":"2","author":"Lee R.","year":"2015","unstructured":"Lee R.; Wong T.Y.; Sabanayagam C.; Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss. Eye Vis (Lond) 2015,2(1),17","journal-title":"Eye Vis (Lond)"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"556","DOI":"10.2337\/dc11-1909","volume":"35","author":"Yau J.W.Y.","year":"2012","unstructured":"Yau J.W.Y.; Rogers S.L.; Kawasaki R.; Lamoureux E.L.; Kowalski J.W.; Bek T.; Chen S.J.; Dekker J.M.; Fletcher A.; Grauslund J.; Haffner S.; Hamman R.F.; Ikram M.K.; Kayama T.; Klein B.E.; Klein R.; Krishnaiah S.; Mayurasakorn K.; O\u2019Hare J.P.; Orchard T.J.; Porta M.; Rema M.; Roy M.S.; Sharma T.; Shaw J.; Taylor H.; Tielsch J.M.; Varma R.; Wang J.J.; Wang N.; West S.; Xu L.; Yasuda M.; Zhang X.; Mitchell P.; Wong T.Y.; Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care Meta-Analysis for Eye Disease (META-EYE) Study Group2012,35(3),556-564","journal-title":"Diabetes Care"},{"key":"ref=7","author":"Guidelines I.C.O.","year":"2017","unstructured":"Guidelines I.C.O.; Care E.; Wong T-Y.; Aiello L.P.; Ferris F.L.; Gupta N.; ICO Guidelines for Diabetic Eye Car 2017","journal-title":"ICO Guidelines for Diabetic Eye Car"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1111\/ceo.12696","author":"Ting D.S.W.","year":"2016","unstructured":"Ting D.S.W.; Cheung G.C.M.; Wong T.Y.; Vol 44, Clinical and Experimental Ophthalmology 2016,260-77","journal-title":"Vol 44, Clinical and Experimental Ophthalmology"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/nrendo.2011.183","author":"Chen L.","year":"2012","unstructured":"Chen L.; Magliano D.J.; Zimmet P.Z.; The worldwide epidemiology of type 2 diabetes mellitus - Present and future perspectives. Vol. 8. Nat Rev Endocrinol 2012,228-236","journal-title":"Nat Rev Endocrinol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"l4894","DOI":"10.1136\/bmj.l4894","volume":"366","author":"Lind M.","year":"2019","unstructured":"Lind M.; Pivodic A.; Svensson A-M.; \u00d3lafsd\u00f3ttir A.F.; Wedel H.; Ludvigsson J.; HbA level as a risk factor for retinopathy and nephropathy in children and adults with type 1 diabetes: Swedish population based cohort study. BMJ 2019,366,l4894","journal-title":"BMJ"},{"year":"2017","author":"Flaxman S.R.","key":"ref=11","unstructured":"Flaxman S.R.; Bourne R.R.A.; Resnikoff S.; Ackland P.; Braithwaite T.; Cicinelli M.V.; Articles Global causes of blindness and distance vision impairment 1990-2020: A systematic review and meta-analysis 2017"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1001\/jama.298.8.902","volume":"298","author":"Mohamed Q","year":"2007","unstructured":"Mohamed Q; Gillies MC; Wong TY; Management of diabetic retinopathy: A systematic review JAM Sci 2007,298,902-16","journal-title":"A systematic review JAM Sci"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/S0140-6736(09)62124-3","volume":"376","author":"Cheung N.","year":"2010","unstructured":"Cheung N.; Mitchell P.; Wong T.Y.; Diabetic retinopathy. Lancet [Internet].2010,376(9735),124-136","journal-title":"Lancet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"5257","DOI":"10.1167\/iovs.07-0112","volume":"48","author":"Leal E.C.","year":"2007","unstructured":"Leal E.C.; Manivannan A.; Hosoya K-I.; Terasaki T.; Cunha-Vaz J.; Ambr\u00f3sio A.F.; Inducible nitric oxide synthase isoform is a key mediator of leukostasis and blood-retinal barrier breakdown in diabetic retinopathy Invest Ophthalmol Vis Sci 2007,48(11),5257-65","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"290","DOI":"10.4239\/wjd.v4.i6.290","volume":"4","author":"Wu L.","year":"2013","unstructured":"Wu L.; Fernandez-Loaiza P.; Sauma J.; Hernandez-Bogantes E.; Masis M.; Hernan-Dez-Bogantes E.; Classification of diabetic retinopathy and diabetic macular edema. World J Diabetes 2013,4(6),290-294","journal-title":"World J Diabetes"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1111\/j.1755-3768.2009.01742.x","volume":"89","author":"Mehlsen J.","year":"2011","unstructured":"Mehlsen J.; Erlandsen M.; Poulsen P.L.; Bek T.; Identification of independent risk factors for the development of diabetic retinopathy requiring treatment Acta Ophthalmol 2011,89(6),515-21","journal-title":"Acta Ophthalmol"},{"key":"ref=17","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2019.107997","volume":"160","author":"Aasbjerg K.","year":"2020","unstructured":"Aasbjerg K.; N\u00f8rgaard C.H.; Vestergaard N.; S\u00f8gaard P.; K\u00f8ber L.; Weeke P.; Gislason G.; Torp-Pedersen C.; Risk of diabetes among related and unrelated family members. Diabetes Res Clin Pract 2020,160","journal-title":"Diabetes Res Clin Pract"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1055\/s-2007-984443","volume":"115","author":"Weires M.B.","year":"2007","unstructured":"Weires M.B.; Tausch B.; Haug P.J.; Edwards C.Q.; Wetter T.; Cannon-Albright L.A.; Familiality of diabetes mellitus. Exp Clin Endocrinol Diabetes 2007,115(10),634-640","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"ref=19","first-page":"1","year":"2017","unstructured":"IDF Diabetes Atlas, 8th edition IDF (International Diabetes Federation)2017,1-150","journal-title":"IDF Diabetes Atlas, 8th edition"},{"key":"ref=20","author":"Rangel \u00c9B","year":"2019","unstructured":"Rangel \u00c9B; Rodrigues CO; De S\u00e1 JR; Micro- and Macrovascular Complications in Diabetes Mellitus: Preclinical and Clinical Studies Journal of Diabetes Research 2019","journal-title":"Journal of Diabetes Research"},{"key":"ref=21","volume":"Vol. 3","author":"Zimmet P.Z.","year":"2017","unstructured":"Zimmet P.Z.; Diabetes and its drivers: The largest epidemic in human history? 2017,Vol. 3","journal-title":"Diabetes and its drivers: The largest epidemic in human history?"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1136\/bmj.38922.650521.80","volume":"333","author":"Marshall S.M.","year":"2006","unstructured":"Marshall S.M.; Flyvbjerg A.; Prevention and early detection of vascular complications of diabetes. BMJ 2006,333(7566),475-480","journal-title":"BMJ"},{"key":"ref=23","first-page":"1","volume":"Vol. 17","author":"Einarson T.R.","year":"2018","unstructured":"Einarson T.R.; Acs A.; Ludwig C.; Panton U.H.; Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017 2018,Vol. 17,1-19","journal-title":"Prevalence of cardiovascular disease in type 2 diabetes: A systematic literature review of scientific evidence from across the world in 2007-2017"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1136\/bmj.38922.650521.80","volume":"333","author":"Marshall SM","year":"2006","unstructured":"Marshall SM; Flyvbjerg A; Clinical Review the Prevention and Early Detection of the Vascular Complications of Diabetes BMJ 2006,333(7566),475-80","journal-title":"BMJ"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1001\/archopht.1985.01050120030015","volume":"103","author":"Edema P.F.D.M.","year":"1985","unstructured":"Edema P.F.D.M.; Photocoagulation for diabetic macular edema. early treatment diabetic retinopathy study report number 1. early treatment diabetic retinopathy study research group. Arch Ophthalmol 1985,103(12),1796-1806","journal-title":"Arch Ophthalmol"},{"year":"2002","key":"ref=26","unstructured":"INTERNATIONAL CLINICAL DIABETIC RETINOPATHY DISEASE SEVERITY SCALE 2002"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1016\/j.ophtha.2013.02.034","volume":"120","author":"Brown D.M.","year":"2013","unstructured":"Brown D.M.; Nguyen Q.D.; Marcus D.M.; Boyer D.S.; Patel S.; Feiner L.; Schlottmann P.G.; Rundle A.C.; Zhang J.; Rubio R.G.; Adamis A.P.; Ehrlich J.S.; Hopkins J.J.; Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology RIDE and RISE Research Group2013,120(10),2013-2022","journal-title":"Ophthalmology"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1016\/j.ophtha.2016.07.032","author":"Heier J.S.","year":"2016","unstructured":"Heier J.S.; Korobelnik J.F.; Brown D.M.; Schmidt-Erfurth U.; Do D.V.; Midena E.; Ophthalmology 2016,2376-2385","journal-title":"Ophthalmology"},{"journal-title":"FDA","key":"ref=29","unstructured":"FDA"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1001\/jamaophthalmol.2014.2854","volume":"132","author":"Varma R.","year":"2014","unstructured":"Varma R.; Bressler N.M.; Doan Q.V.; Gleeson M.; Danese M.; Bower J.K.; Selvin E.; Dolan C.; Fine J.; Colman S.; Turpcu A.; Prevalence of and risk factors for diabetic macular edema in the United States. JAMA Ophthalmol 2014,132(11),1334-1340","journal-title":"JAMA Ophthalmol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/S0161-6420(84)34102-1","volume":"91","author":"Klein R.","year":"1984","unstructured":"Klein R.; Klein B.E.K.; Moss S.E.; Davis M.D.; DeMets D.L.; The Wisconsin epidemiologic study of diabetic retinopathy. IV. Diabetic macular edema. Ophthalmology 1984,91(12),1464-1474","journal-title":"Ophthalmology"},{"key":"ref=32","author":"Lu L","year":"2018","unstructured":"Lu L; Jiang Y; Jaganathan R; Hao Y.; Current Advances in Pharmacotherapy and Technology for Diabetic Retinopathy: A Systematic Review. J Ophthalmol 2018","journal-title":"J Ophthalmol"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/S0161-6420(13)38012-9","volume":"98","year":"1991","unstructured":"Grading diabetic retinopathy from stereoscopic color fundus photographs- an extension of the modified Airlie House classification. ETDRS report number 10. Ophthalmology Early Treatment Diabetic Retinopathy Study Research Group1991,98(5)(Suppl.),786-806","journal-title":"Ophthalmology"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/j.1464-5491.2011.03325.x","volume":"28","author":"Barchetta I.","year":"2011","unstructured":"Barchetta I.; Riccieri V.; Vasile M.; Stefanantoni K.; Comberiati P.; Taverniti L.; High prevalence of capillary abnormalities in patients with diabetes and association with retinopathy Diabet Med 2011,28(9),1039-44","journal-title":"Diabet Med"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1167\/iovs.07-1440","volume":"49","author":"Wu M.","year":"2008","unstructured":"Wu M.; Chen Y.; Wilson K.; Chirindel A.; Ihnat M.A.; Yu Y.; Boulton M.E.; Szweda L.I.; Ma J.X.; Lyons T.J.; Intraretinal leakage and oxidation of LDL in diabetic retinopathy. Invest Ophthalmol Vis Sci 2008,49(6),2679-2685","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/0039-6257(84)90227-3","volume":"28","author":"Ferris F.L.","year":"1984","unstructured":"Ferris F.L.; Patz A.; Macular edema. A complication of diabetic retinopathy. Surv Ophthalmol 1984,28,452-461","journal-title":"Surv Ophthalmol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/S0161-6420(87)33527-4","volume":"94","year":"1987","unstructured":"Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Ophthalmology Early Treatment Diabetic Retinopathy Study Research Group1987,94(7),761-774","journal-title":"Ophthalmology"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/S0161-6420(13)38011-7","volume":"98","year":"1991","unstructured":"Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Ophthalmology Early Treatment Diabetic Retinopathy Study Research Group1991,98(5)(Suppl.),766-785","journal-title":"Ophthalmology"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.optom.2013.03.003","volume":"7","author":"Shrestha G.S.","year":"2014","unstructured":"Shrestha G.S.; Kaiti R.; Visual functions and disability in diabetic retinopathy patients. J Optom 2014,7(1),37-43","journal-title":"J Optom"},{"key":"ref=40","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007419.pub6","volume":"10","author":"Virgili G.","year":"2018","unstructured":"Virgili G.; Parravano M.; Evans J.R.; Gordon I.; Lucenteforte E.; Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev 2018,10(10)","journal-title":"Cochrane Database Syst Rev"},{"journal-title":"DrugBank","key":"ref=41","unstructured":"DrugBank"},{"key":"ref=42","author":"Flockhart D.A.","year":"2007","unstructured":"Flockhart D.A.; Drug Interactions: Cytochrome P450 Drug Interaction Table Indiana University School of Medicine 2007","journal-title":"Indiana University School of Medicine"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1016\/j.cellsig.2007.05.013","volume":"19","author":"Holmes K.","year":"2007","unstructured":"Holmes K.; Roberts O.L.; Thomas A.M.; Cross M.J.; Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal 2007,19(10),2003-2012","journal-title":"Cell Signal"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s11030-006-9027-3","volume":"10","author":"Yamazaki Y.","year":"2006","unstructured":"Yamazaki Y.; Morita T.; Molecular and functional diversity of vascular endothelial growth factors. Mol Divers 2006,10(4),515-527","journal-title":"Mol Divers"},{"year":"2013","author":"Duffy AM","key":"ref=45","unstructured":"Duffy AM; Bouchier-Hayes DJ; Harmey JH; Vascular Endothelial Growth Factor (VEGF) and Its Role in Non-Endothelial Cells: Autocrine Signalling by VEGF 2013"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"112","DOI":"10.4103\/0974-620X.142591","author":"Al-Halafi AM","year":"2014","unstructured":"Al-Halafi AM; Vascular endothelial growth factor trap-eye and trap technology: Aflibercept from bench to bedsid Vol 7, Oman Journal of Ophthalmology 2014,112-5","journal-title":"Vol 7, Oman Journal of Ophthalmology"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"5141","DOI":"10.1073\/pnas.94.10.5141","volume":"94","author":"Eichmann A.","year":"1997","unstructured":"Eichmann A.; Corbel C.; Nataf V.; Vaigot P.; Br\u00e9ant C.; Le Douarin N.M.; Ligand-dependent development of the endothelial and hemopoietic lineages from embryonic mesodermal cells expressing vascular endothelial growth factor receptor 2. Proc Natl Acad Sci USA 1997,94(10),5141-5146","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"30336","DOI":"10.1074\/jbc.273.46.30336","volume":"273","author":"Gerber H.P.","year":"1998","unstructured":"Gerber H.P.; McMurtrey A.; Kowalski J.; Yan M.; Keyt B.A.; Dixit V.; Ferrara N.; Vascular endothelial growth factor regulates endothelial cell survival through the phosphatidylinositol 3\u2032-kinase\/Akt signal transduction pathway. Requirement for Flk-1\/KDR activation. J Biol Chem 1998,273(46),30336-30343","journal-title":"J Biol Chem"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1172\/JCI114322","volume":"84","author":"Connolly D.T.","year":"1989","unstructured":"Connolly D.T.; Heuvelman D.M.; Nelson R.; Olander J.V.; Eppley B.L.; Delfino J.J.; Siegel N.R.; Leimgruber R.M.; Feder J.; Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 1989,84(5),1470-1478","journal-title":"J Clin Invest"},{"key":"ref=50","first-page":"818","volume":"Vol. 11","author":"Rahimi N.","year":"2006","unstructured":"Rahimi N.; VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy 2006,Vol. 11,818-829","journal-title":"VEGFR-1 and VEGFR-2: Two non-identical twins with a unique physiognomy"},{"key":"ref=51","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1002\/jcb.21579","author":"Breen E.C.","year":"2007","unstructured":"Breen E.C.; VEGF in biological control Vol 102, Journal of Cellular Biochemistry 2007,1358-67","journal-title":"Vol 102, Journal of Cellular Biochemistry"},{"key":"ref=52","first-page":"359","volume":"Vol. 7","author":"Olsson A.K.","year":"2006","unstructured":"Olsson A.K.; Dimberg A.; Kreuger J.; Claesson-Welsh L.; VEGF receptor signalling - In control of vascular function Internet2006,Vol. 7,359-371","journal-title":"VEGF receptor signalling - In control of vascular function"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/s41433-018-0021-7","volume":"32","author":"Fogli S.","year":"2018","unstructured":"Fogli S.; Del Re M.; Rofi E.; Posarelli C.; Figus M.; Danesi R.; Eye 2018,32,1010-1020","journal-title":"Eye"},{"key":"ref=54","first-page":"2080","volume":"114","author":"Bro T.","year":"2017","unstructured":"Bro T.; An eye for an eye? Lack of consensus in off-label use of medications leads to major regional differences in medical costs for the treatment of wet AMD in Sweden. Lakartidningen 2017,114(48),2080","journal-title":"Lakartidningen"},{"key":"ref=55","unstructured":"DailyMed - MACUGEN- pegaptanib sodium injection, solution"},{"key":"ref=56","unstructured":"DailyMed - EYLEA- aflibercept injection, solution"},{"key":"ref=57","unstructured":"DailyMed - BEOVU- brolucizumab injection, solution"},{"key":"ref=58","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","author":"Dugel P.U.","year":"2020","unstructured":"Dugel P.U.; Koh A.; Ogura Y.; Jaffe G.J.; Schmidt-Erfurth U.; Brown D.M.; Ophthalmology 2020,72-84","journal-title":"Ophthalmology"},{"key":"ref=59","unstructured":"DailyMed - LUCENTIS- ranibizumab injection, solution"},{"key":"ref=60","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000006965","author":"Nagai N","year":"2017","unstructured":"Nagai N; Ibuki M; Shinoda H; Kameyama K; Tsubota K; Ozawa Y; Maculopapular rash after intravitreal injection of an antivascular endothelial growth factor, aflibercept, for treating age-related macular degeneration Med 2017","journal-title":"Med"},{"key":"ref=61","first-page":"153","volume":"Vol. 29","author":"Rosenwasser G.O.D.","year":"1989","unstructured":"Rosenwasser G.O.D.; Complications of topical ocular anesthetics Internet1989,Vol. 29,153-158","journal-title":"Complications of topical ocular anesthetics"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ophtha.2012.09.006","volume":"119","author":"Heier J.S.","year":"2012","unstructured":"Heier J.S.; Brown D.M.; Chong V.; Korobelnik J.F.; Kaiser P.K.; Nguyen Q.D.; Kirchhof B.; Ho A.; Ogura Y.; Yancopoulos G.D.; Stahl N.; Vitti R.; Berliner A.J.; Soo Y.; Anderesi M.; Groetzbach G.; Sommerauer B.; Sandbrink R.; Simader C.; Schmidt-Erfurth U.; Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology VIEW 1 and VIEW 2 Study Groups2012,119(12),2537-2548","journal-title":"Ophthalmology"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"Falavarjani K.G.","year":"2013","unstructured":"Falavarjani K.G.; Nguyen Q.D.; Eye 2013,27,787-794","journal-title":"Eye"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"212","DOI":"10.22336\/rjo.2018.32","volume":"62","author":"Maryam A.K.","year":"2018","unstructured":"Maryam A.K.; Tafgeh M.; Mahmoud M.; Pasha A.; Ahad S.; Khalil G.F.; Short term effect of intravitreal bevacizumab for diabetic macular edema associated with epiretinal membrane Rom J Ophthalmol 2018,62(3),212-6","journal-title":"Rom J Ophthalmol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1038\/s41598-020-57509-6","volume":"10","author":"Kang Y.K.","year":"2020","unstructured":"Kang Y.K.; Park H.S.; Park D.H.; Shin J.P.; Incidence and treatment outcomes of secondary epiretinal membrane following intravitreal injection for diabetic macular edema. Sci Rep 2020,10(1),528","journal-title":"Sci Rep"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1001\/jamaophthalmol.2015.4070","volume":"134","author":"Avery R.L.","year":"2016","unstructured":"Avery R.L.; Gordon G.M.; Systemic safety of prolonged monthly anti-vascular endothelial growth factor therapy for diabetic macular edema: A systematic review and meta-analysis JAMA Ophthalmol 2016,134(1),21-9","journal-title":"JAMA Ophthalmol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1056\/NEJMoa042760","volume":"351","author":"Gragoudas E.S.","year":"2004","unstructured":"Gragoudas E.S.; Adamis A.P.; Cunningham E.T.; Feinsod M.; Guyer D.R.; Pegaptanib for neovascular age-related macular degeneration. N Engl J Med VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group2004,351(27),2805-2816","journal-title":"N Engl J Med"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1038\/nrd1955","volume":"5","author":"Ng E.W.M.","year":"2006","unstructured":"Ng E.W.M.; Shima D.T.; Calias P.; Cunningham E.T.; Guyer D.R.; Adamis A.P.; Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat Rev Drug Discov 2006,5(2),123-132","journal-title":"Nat Rev Drug Discov"},{"key":"ref=69","unstructured":"Drug Approval Package: Macugen"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1136\/bjophthalmol-2013-304075","volume":"98","author":"Boyer D.S.","year":"2014","unstructured":"Boyer D.S.; Goldbaum M.; Leys A.M.; Starita C.; Effect of pegaptanib sodium 0.3\u2005mg intravitreal injections (Macugen) in intraocular pressure: posthoc analysis from V.I.S.I.O.N. study. Br J Ophthalmol 2014,98(11),1543-1546","journal-title":"Br J Ophthalmol"},{"year":"2020","key":"ref=71","unstructured":"EMA 2020"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1517\/14712598.7.5.739","volume":"7","author":"Cilley J.C.","year":"2007","unstructured":"Cilley J.C.; Barfi K.; Benson A.B.; Mulcahy M.F.; Bevacizumab in the treatment of colorectal cancer Expert Opin Biol Ther 2007,7(5),739-49","journal-title":"Expert Opin Biol Ther"},{"year":"2019","key":"ref=73","unstructured":"EMA 2019"},{"key":"ref=74","first-page":"1689","volume":"53","author":"Oliver J.","year":"2013","unstructured":"Oliver J.; \u6e08\u7121. J Chem Inf Model 2013,53(9),1689-99"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/jamaophthalmol.2015.4110","volume":"134","author":"Heier J.S.","year":"2016","unstructured":"Heier J.S.; Bressler N.M.; Avery R.L.; Bakri S.J.; Boyer D.S.; Brown D.M.; Dugel P.U.; Freund K.B.; Glassman A.R.; Kim J.E.; Martin D.F.; Pollack J.S.; Regillo C.D.; Rosenfeld P.J.; Schachat A.P.; Wells J.A.; Comparison of aflibercept, bevacizumab, and ranibizumab for treatment of diabetic macular edema: Extrapolation of data to clinical practice. JAMA Ophthalmol 2016,134(1),95-99","journal-title":"JAMA Ophthalmol"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","volume":"372","author":"Wells J.A.","year":"2015","unstructured":"Wells J.A.; Glassman A.R.; Ayala A.R.; Jampol L.M.; Aiello L.P.; Antoszyk A.N.; Arnold-Bush B.; Baker C.W.; Bressler N.M.; Browning D.J.; Elman M.J.; Ferris F.L.; Friedman S.M.; Melia M.; Pieramici D.J.; Sun J.K.; Beck R.W.; Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med 2015,372(13),1193-1203","journal-title":"N Engl J Med"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00228-012-1232-7","volume":"68","author":"Taugourdeau-Raymond S.","year":"2012","unstructured":"Taugourdeau-Raymond S.; Rouby F.; Default A.; Jean-Pastor M.J.; Bevacizumab-induced serious side-effects: A review of the French pharmacovigilance database Eur J Clin Pharmacol 2012,68(7),1103-7","journal-title":"Eur J Clin Pharmacol"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/nrd2157","volume":"5","author":"Narayanan R.","year":"2006","unstructured":"Narayanan R.; Kuppermann B.D.; Jones C.; Kirkpatrick P.; Ranibizumab. Nat Rev Drug Discov 2006,5(10),815-816","journal-title":"Nat Rev Drug Discov"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"252","DOI":"10.3109\/08820538.2013.859280","volume":"30","author":"Gardlik R.","year":"2015","unstructured":"Gardlik R.; Fusekova I.; Pharmacologic therapy for diabetic retinopathy. Semin Ophthalmol 2015,30(4),252-263","journal-title":"Semin Ophthalmol"},{"key":"ref=80","first-page":"185","author":"Schmidt-Erfurth U.","year":"2017","unstructured":"Schmidt-Erfurth U.; Garcia-Arumi J.; Bandello F.; Berg K.; Chakravarthy U.; Gerendas B.S.; Vol 237, Ophthalmologica S Karger AG 2017,185-222","journal-title":"Vol 237, Ophthalmologica S Karger AG"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.ophtha.2011.01.031","volume":"118","author":"Mitchell P.","year":"2011","unstructured":"Mitchell P.; Bandello F.; Schmidt-Erfurth U.; Lang G.E.; Massin P.; Schlingemann R.O.; Sutter F.; Simader C.; Burian G.; Gerstner O.; Weichselberger A.; The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011,118(4),615-625","journal-title":"Ophthalmology"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamaophthalmol.2019.4284","volume":"33647","author":"Hutton D.W.","year":"2019","unstructured":"Hutton D.W.; Stein J.D.; Glassman A.R.; Bressler N.M.; Jampol L.M.; Sun J.K.; Five-year cost-effectiveness of intravitreous ranibizumab therapy vs panretinal photocoagulation for treating proliferative diabetic retinopathy: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol [Internet].2019,33647,1-9","journal-title":"JAMA Ophthalmol"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1136\/bjophthalmol-2015-307249","volume":"100","author":"Pr\u00fcnte C.","year":"2016","unstructured":"Pr\u00fcnte C.; Fajnkuchen F.; Mahmood S.; Ricci F.; Hatz K.; Studni\u010dka J.; Bezlyak V.; Parikh S.; Stubbings W.J.; Wenzel A.; Figueira J.; Ranibizumab 0.5\u2005mg treat-and-extend regimen for diabetic macular oedema: the RETAIN study. Br J Ophthalmol 2016,100(6),787-795","journal-title":"Br J Ophthalmol"},{"key":"ref=84","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0115797","volume":"9","author":"Chen G.","year":"2014","unstructured":"Chen G.; Li W.; Tzekov R.; Jiang F.; Mao S.; Tong Y.; Ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema: A meta-analysis of randomized controlled trials. PLoS One 2014,9(12)","journal-title":"PLoS One"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"11393","DOI":"10.1073\/pnas.172398299","volume":"99","author":"Holash J.","year":"2002","unstructured":"Holash J.; Davis S.; Papadopoulos N.; Croll S.D.; Ho L.; Russell M.; Boland P.; Leidich R.; Hylton D.; Burova E.; Ioffe E.; Huang T.; Radziejewski C.; Bailey K.; Fandl J.P.; Daly T.; Wiegand S.J.; Yancopoulos G.D.; Rudge J.S.; VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 2002,99(17),11393-11398","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1167\/iovs.04-0601","volume":"46","author":"Gaudreault J.","year":"2005","unstructured":"Gaudreault J.; Fei D.; Rusit J.; Suboc P.; Shiu V.; Preclinical pharmacokinetics of Ranibizumab (rhuFabV2) after a single intravitreal administration. Invest Ophthalmol Vis Sci 2005,46(2),726-733","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3186","DOI":"10.1167\/iovs.02-1092","volume":"44","author":"Rakic J.M.","year":"2003","unstructured":"Rakic J.M.; Lambert V.; Devy L.; Luttun A.; Carmeliet P.; Claes C.; Nguyen L.; Foidart J.M.; No\u00ebl A.; Munaut C.; Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 2003,44(7),3186-3193","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10456-011-9249-6","volume":"15","author":"Papadopoulos N.","year":"2012","unstructured":"Papadopoulos N.; Martin J.; Ruan Q.; Rafique A.; Rosconi M.P.; Shi E.; Pyles E.A.; Yancopoulos G.D.; Stahl N.; Wiegand S.J.; Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012,15(2),171-185","journal-title":"Angiogenesis"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1167\/iovs.16-19204","volume":"57","author":"Park S.J.","year":"2016","unstructured":"Park S.J.; Choi Y.; Na Y.M.; Hong H.K.; Park J.Y.; Park K.H.; Chung J.Y.; Woo S.J.; Intraocular pharmacokinetics of intravitreal aflibercept (Eylea) in a rabbit model. Invest Ophthalmol Vis Sci 2016,57(6),2612-2617","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.ophtha.2016.02.022","volume":"123","author":"Wells J.A.","year":"2016","unstructured":"Wells J.A.; Glassman A.R.; Ayala A.R.; Jampol L.M.; Bressler N.M.; Bressler S.B.; Brucker A.J.; Ferris F.L.; Hampton G.R.; Jhaveri C.; Melia M.; Beck R.W.; Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema: two-year results from a comparative effectiveness randomized clinical trial. Ophthalmology 2016,123(6),1351-1359","journal-title":"Ophthalmology"},{"key":"ref=91","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.ajo.2018.07.030","volume":"195","author":"Bressler N.M.","year":"2018","unstructured":"Bressler N.M.; Beaulieu W.T.; Maguire M.G.; Glassman A.R.; Blinder K.J.; Bressler S.B.; Early response to anti\u2013vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol t Am J Ophthalmol 2018,195(93),100","journal-title":"Am J Ophthalmol"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.ophtha.2013.02.019","volume":"120","author":"Lang G.E.","year":"2013","unstructured":"Lang G.E.; Berta A.; Eldem B.M.; Simader C.; Sharp D.; Holz F.G.; Sutter F.; Gerstner O.; Mitchell P.; Two-year safety and efficacy of ranibizumab 0.5 mg in diabetic macular edema: Interim analysis of the RESTORE extension study. Ophthalmology 2013,120(10),2004-2012","journal-title":"Ophthalmology"},{"key":"ref=93","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.ophtha.2013.11.041","volume":"121","author":"Schmidt-Erfurth U.","year":"2014","unstructured":"Schmidt-Erfurth U.; Lang G.E.; Holz F.G.; Schlingemann R.O.; Lanzetta P.; Massin P.; Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study Ophthalmology 2014,121(5),1045-53","journal-title":"Ophthalmology"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"2399","DOI":"10.2337\/dc10-0493","volume":"33","author":"Massin P.","year":"2010","unstructured":"Massin P.; Bandello F.; Garweg J.G.; Hansen L.L.; Harding S.P.; Larsen M.; Mitchell P.; Sharp D.; Wolf-Schnurrbusch U.E.; Gekkieva M.; Weichselberger A.; Wolf S.; Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12- month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010,33(11),2399-2405","journal-title":"Diabetes Care"},{"key":"ref=95","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ophtha.2015.09.002","volume":"123","author":"Solomon S.D.","year":"2016","unstructured":"Solomon S.D.; Lindsley K.B.; Krzystolik M.G.; Vedula S.S.; Hawkins B.S.; Intravitreal bevacizumab versus ranibizumab for treatment of neovascular age-related macular degeneration: findings from a cochrane systematic review Ophthalmology 2016,123(1),70-77","journal-title":"Ophthalmology"},{"key":"ref=96","unstructured":""},{"key":"ref=97","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/j.ophtha.2015.12.030","volume":"123","author":"Holz F.G.","year":"2016","unstructured":"Holz F.G.; Dugel P.U.; Weissgerber G.; Hamilton R.; Silva R.; Bandello F.; Single-chain antibody fragment VEGF inhibitor RTH258 for neovascular age-related macular degeneration: a randomized controlled study Ophthalmology 2016,123(5),1080-9","journal-title":"Ophthalmology"},{"key":"ref=98","author":"Nimz E.L.","year":"2016","unstructured":"Nimz E.L.; Meeting TA for R in V and O (ARVO) annual, editor 2016","journal-title":"Meeting TA for R in V and O (ARVO) annual, editor"},{"key":"ref=99","unstructured":"A study of the efficacy and safety of brolucizumab vs aflibercept in patients with visual impairment due to diabetic macular edema - full text view - clinicaltrials.gov"},{"key":"ref=100","unstructured":"Study of efficacy and safety of brolucizumab vs. aflibercept in patients with visual impairment due to diabetic macular edema - full text view - clinicaltrials.gov"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1007\/s40265-019-01231-9","volume":"79","author":"Markham A.","year":"2019","unstructured":"Markham A.; Brolucizumab: First Approval. Drugs 2019,79(18),1997-2000","journal-title":"Drugs"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.15252\/emmm.201505889","volume":"8","author":"Regula J.T.","year":"2016","unstructured":"Regula J.T.; Lundh von Leithner P.; Foxton R.; Barathi V.A.; Cheung C.M.G.; Bo Tun S.B.; Wey Y.S.; Iwata D.; Dostalek M.; Moelleken J.; Stubenrauch K.G.; Nogoceke E.; Widmer G.; Strassburger P.; Koss M.J.; Klein C.; Shima D.T.; Hartmann G.; Targeting key angiogenic pathways with a bispecific CrossMAb optimized for neovascular eye diseases. EMBO Mol Med 2016,8(11),1265-1288","journal-title":"EMBO Mol Med"},{"key":"ref=103","first-page":"21","author":"Klein C.","year":"2019","unstructured":"Klein C.; Schaefer W.; Regula J.T.; Dumontet C.; Brinkmann U.; Bacac M.; Engineering therapeutic bispecific antibodies using CrossMab technology Vol 154, Methods Academic Press Inc 2019,21-31","journal-title":"Vol 154, Methods Academic Press Inc"},{"key":"ref=104","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.ophtha.2019.03.023","volume":"126","author":"Sahni J","year":"2019","unstructured":"Sahni J; Patel SS; Dugel PU; Khanani AM; Jhaveri CD; Wykoff CC; Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial Ophthalmology 2019,126(8),1155-70","journal-title":"Ophthalmology"},{"year":"2019","key":"ref=105","unstructured":"Csaky KG. Data supporting the sustained efficacy o; Oct. 11-15; San Francisco.; a bispecific antibody neutralizing both angiopoiet KG C.2019"},{"key":"ref=106","unstructured":"A Study to Evaluate the Efficacy and Safety of Faricimab (RO6867461) in Participants With Diabetic Macular Edema (YOSEMITE)"},{"key":"ref=107","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0670-1","volume":"10\u20132","author":"Sharma A.","year":"2019","unstructured":"Sharma A.; Kumar N.; Kuppermann B.D.; Bandello F.; Loewenstein A.; Faricimab: Expanding horizon beyond VEGF. Eye (Lond) [Internet].2019,10\u20132","journal-title":"Eye (Lond)"},{"key":"ref=108","unstructured":"KG C. HEALIO"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"3471","DOI":"10.2147\/DDDT.S177192","author":"Cai S.","year":"2018","unstructured":"Cai S.; Yang Q.; Li X.; Zhang Y.; Vol 12, Drug Design, Development and Therapy 2018,3471-83","journal-title":"Vol 12, Drug Design, Development and Therapy"},{"key":"ref=110","first-page":"37","volume":"14","author":"Zhang M.","year":"2008","unstructured":"Zhang M.; Zhang J.; Yan M.; Li H.; Yang C.; Yu D.; Recombinant anti-vascular endothelial growth factor fusion protein efficiently suppresses choridal neovasularization in monkeys. Mol Vis 2008,14,37-49","journal-title":"Mol Vis"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.1074\/jbc.M411395200","volume":"280","author":"Suto K.","year":"2005","unstructured":"Suto K.; Yamazaki Y.; Morita T.; Mizuno H.; Crystal structures of novel vascular endothelial growth factors (VEGF) from snake venoms: insight into selective VEGF binding to kinase insert domain- containing receptor but not to fms-like tyrosine kinase-1. J Biol Chem 2005,280(3),2126-2131","journal-title":"J Biol Chem"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/s11095-008-9718-9","volume":"26","author":"Zhang M.","year":"2009","unstructured":"Zhang M.; Yu D.; Yang C.; Xia Q.; Li W.; Liu B.; Li H.; The pharmacology study of a new recombinant human VEGF receptor-fc fusion protein on experimental choroidal neovascularization. Pharm Res 2009,26(1),204-210","journal-title":"Pharm Res"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.exer.2011.09.002","volume":"97","author":"Li H.","year":"2012","unstructured":"Li H.; Lei N.; Zhang M.; Li Y.; Xiao H.; Hao X.; Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 2012,97(1),154-159","journal-title":"Exp Eye Res"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","volume":"197","author":"Liu K.","year":"2019","unstructured":"Liu K.; Song Y.; Xu G.; Ye J.; Wu Z.; Liu X.; Dong X.; Zhang M.; Xing Y.; Zhu S.; Chen X.; Shen Y.; Huang H.; Yu L.; Ke Z.; Rosenfeld P.J.; Kaiser P.K.; Ying G.; Sun X.; Xu X.; Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized phase 3 PHOENIX study. Am J Ophthalmol PHOENIX study group2019,197,156-167","journal-title":"Am J Ophthalmol"},{"key":"ref=115","unstructured":"Efficacy and safety trial of conbercept intravitreal injection for neovascular age-related macular degeneration (PANDA-1)"},{"key":"ref=116","unstructured":"Efficacy and safety trial of conbercept intravitreal injection for neovascular age-related macular degeneration (PANDA-2)"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/eye.2012.287","volume":"27","author":"Ghanchi F.","year":"2013","unstructured":"Ghanchi F.; Bailey C.; Chakravarthy U.; Cohen S.; Dodson P.; Gibson J.; the royal college of ophthalmologists\u2019 clinical guidelines for diabetic retinopathy: a summary. Eye (Lond) Diabetic retinopathy guidelines working group2013,27(2),285-287","journal-title":"Eye (Lond)"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"100","DOI":"10.2174\/1573399810666140402123026","volume":"10","author":"Romero-Aroca P.","year":"2014","unstructured":"Romero-Aroca P.; Reyes-Torres J.; Baget-Bernaldiz M.; Blasco- Su\u00f1e C.; Laser treatment for diabetic macular edema in the 21st century. Curr Diabetes Rev 2014,10(2),100-112","journal-title":"Curr Diabetes Rev"},{"key":"ref=119","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","volume":"119","author":"Nguyen Q.D.","year":"2012","unstructured":"Nguyen Q.D.; Brown D.M.; Marcus D.M.; Boyer D.S.; Patel S.; Feiner L.; Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012,119(4),789-801","journal-title":"Ophthalmology"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1001\/jama.2015.15217","volume":"314","author":"Gross J.G.","year":"2015","unstructured":"Gross J.G.; Glassman A.R.; Jampol L.M.; Inusah S.; Aiello L.P.; Antoszyk A.N.; Baker C.W.; Berger B.B.; Bressler N.M.; Browning D.; Elman M.J.; Ferris F.L.; Friedman S.M.; Marcus D.M.; Melia M.; Stockdale C.R.; Sun J.K.; Beck R.W.; Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: A randomized clinical trial. JAMA -. JAMA 2015,314(20),2137-2146","journal-title":"JAMA"},{"key":"ref=121","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010859.pub2","volume":"10","author":"Jorge E.C.E.N.","year":"2018","unstructured":"Jorge E.C.E.N.; Jorge E.N.; Botelho M.; Farat J.G.; Virgili G.; El Dib R.; Monotherapy laser photocoagulation for diabetic macular oedema. Cochrane Database Syst Rev 2018,10(10)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=122","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1136\/bjo.2008.146712","volume":"93","author":"Figueira J.","year":"2009","unstructured":"Figueira J.; Khan J.; Nunes S.; Sivaprasad S.; Rosa A.; de Abreu J.F.; Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema Br J Ophthalmol 2009,93(10),1341-4","journal-title":"Br J Ophthalmol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12886-018-0841-z","volume":"18","author":"Chhablani J.","year":"2018","unstructured":"Chhablani J.; Alshareef R.; Kim D.T.; Narayanan R.; Goud A.; Mathai A.; Comparison of different settings for yellow subthreshold laser treatment in diabetic macular edema. BMC Ophthalmol 2018,18(1),168","journal-title":"BMC Ophthalmol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1159\/000459691","volume":"60","author":"Lattanzio R.","year":"2017","unstructured":"Lattanzio R.; Cicinelli M.V.; Bandello F.; Intravitreal Steroids in Diabetic Macular Edema. Dev Ophthalmol 2017,60,78-90","journal-title":"Dev Ophthalmol"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0079-6107(02)00037-8","volume":"81","author":"Gonz\u00e1lez-Mariscal L.","year":"2003","unstructured":"Gonz\u00e1lez-Mariscal L.; Betanzos A.; Nava P.; Jaramillo B.E.; Tight junction proteins. Prog Biophys Mol Biol 2003,81(1),1-44","journal-title":"Prog Biophys Mol Biol"},{"key":"ref=126","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.2337\/db09-1216","volume":"59","author":"White N.H.","year":"2010","unstructured":"White N.H.; Sun W.; Cleary P.A.; Tamborlane W.V.; Danis R.P.; Hainsworth D.P.; Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT\/EDIC: Comparison of adults and adolescents Diabetes 2010,59(5),1244-53","journal-title":"Diabetes"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/2045-3701-4-27","volume":"4","author":"Zhang X.","year":"2014","unstructured":"Zhang X.; Zeng H.; Bao S.; Wang N.; Gillies M.C.; Diabetic macular edema: new concepts in patho-physiology and treatment Cell Biosci 2014,4(1),27","journal-title":"Cell Biosci"},{"key":"ref=128","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1016\/j.ophtha.2007.05.062","volume":"114","year":"2007","unstructured":"A Phase II Randomized Clinical Trial of Intravitreal Bevacizumab for Diabetic Macular Edema Ophthalmology Diabetic Retinopathy Clinical Research Network, Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, et al2007,114(10),1860-7","journal-title":"Ophthalmology"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.ajo.2011.03.033","volume":"152","author":"Sohn H.J.","year":"2011","unstructured":"Sohn H.J.; Han D.H.; Kim I.T.; Oh I.K.; Kim K.H.; Lee D.Y.; Changes in aqueous concentrations of various cytokines after intravitreal triamcinolone versus bevacizumab for diabetic macular edema Am J Ophthalmol 2011,152(4),686-94","journal-title":"Am J Ophthalmol"},{"key":"ref=130","first-page":"523","volume":"115","author":"Sakamoto T.","year":"2011","unstructured":"Sakamoto T.; Ishibashi T.; Ogura Y.; Shiraga F.; Takeuchi S.; Yamashita H.; [Survey of triamcinolone-related non-infectious endophthalmitis] Nihon Ganka Gakkai Zasshi 2011,115(6),523-8","journal-title":"Nihon Ganka Gakkai Zasshi"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1016\/j.ajo.2005.10.004","volume":"141","author":"Quiram P.A.","year":"2006","unstructured":"Quiram P.A.; Gonzales C.R.; Schwartz S.D.; Severe steroid-induced glaucoma following intravitreal injection of triamcinolone acetonide Am J Ophthalmol 2006,141(3),580-2","journal-title":"Am J Ophthalmol"},{"key":"ref=132","author":"Pacella F","year":"2016","unstructured":"Pacella F; Ferraresi AF; Turchetti P; Lenzi T; Giustolisi R; Bottone A; Intravitreal injection of ozurdex\u00ae implant in patients with persistent diabetic macular edema, with six-month follow-up Ophthalmol Eye Dis 2016","journal-title":"Ophthalmol Eye Dis"},{"key":"ref=133","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/989501","author":"Sarao V.","year":"2014","unstructured":"Sarao V.; Veritti D.; Boscia F.; Lanzetta P.; Intravitreal steroids for the treatment of retinal diseases ScientificWorldJournal 2014","journal-title":"ScientificWorldJournal"},{"key":"ref=134","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1001\/archophthalmol.2008.610","volume":"127","author":"Beck R.W.","year":"2009","unstructured":"Beck R.W.; Edwards A.R.; Aiello L.P.; Bressler N.M.; Ferris F.; Glassman A.R.; Three-year follow-up of a randomized trial comparing focal\/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema Arch Ophthalmol 2009,127(3),245-51","journal-title":"Arch Ophthalmol"},{"key":"ref=135","first-page":"1149","volume":"115","year":"2008","unstructured":"A Randomized Trial Comparing Intravitreal Triamcinolone Acetonide and Focal\/Grid Photocoagulation for Diabetic Macular Edema Ophthalmology Diabetic Retinopathy Clinical Research Network2008,115(9),1149","journal-title":"Ophthalmology"},{"key":"ref=136","first-page":"1427","volume":"9","author":"Pacella F.","year":"2016","unstructured":"Pacella F.; Romano M.R.; Turchetti P.; Tarquini G.; Carnovale A.; Mollicone A.; Mastromatteo A.; Pacella E.; An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol 2016,9(10),1427-1432","journal-title":"Int J Ophthalmol"},{"year":"2014","key":"ref=137","unstructured":"HIGHLIGHTS OF PRESCRIBING INFORMATION OZURDEX FDA2014"},{"key":"ref=138","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1001\/jamaophthalmol.2017.4914","volume":"136","author":"Maturi R.K.","year":"2018","unstructured":"Maturi R.K.; Glassman A.R.; Liu D.; Beck R.W.; Bhavsar A.R.; Bressler N.M.; Jampol L.M.; Melia M.; Punjabi O.S.; Salehi-Had H.; Sun J.K.; Effect of adding dexamethasone to continued ranibizumab treatment in patients with persistent diabetic macular edema: A DRCR network phase 2 randomized clinical trial. JAMA Ophthalmol 2018,136(1),29-38","journal-title":"JAMA Ophthalmol"},{"key":"ref=139","first-page":"1843","author":"Callanan D.G.","year":"2013","unstructured":"Callanan D.G.; Gupta S.; Boyer D.S.; Ciulla T.A.; Singer M.A.; Kuppermann B.D.; Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema [Internet]2013,1843-1851","journal-title":"Dexamethasone intravitreal implant in combination with laser photocoagulation for the treatment of diffuse diabetic macular edema"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jfo.2014.08.003","volume":"38","author":"Degoumois A.","year":"2015","unstructured":"Degoumois A.; Akesbi J.; Laurens C.; Rodallec F.T.; Adam R.; Blumen-Ohana E.; Laplace O.; Virevialle C.; Le D\u00fb B.; Guyader V.; Nordmann J.P.; Efficacit\u00e9 des implants intravitr\u00e9ens de dexam\u00e9thasone dans l\u2019\u0153d\u00e8me maculaire hors occlusions veineuses\u00a0: r\u00e9sultats sur une cohorte de 80\u00a0patients. J Fr Ophtalmol 2015,38(2),126-133","journal-title":"J Fr Ophtalmol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1097\/IAE.0b013e318206d18c","volume":"31","author":"Boyer D.S.","year":"2011","unstructured":"Boyer D.S.; Faber D.; Gupta S.; Patel S.S.; Tabandeh H.; Li X.Y.; Dexamethasone intravitreal implant for treatment of diabetic macular edema in vitrectomized patients Retina 2011,31(5),915-23","journal-title":"Retina"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.ophtha.2012.04.030","volume":"119","author":"Campochiaro P.A.","year":"2012","unstructured":"Campochiaro P.A.; Brown D.M.; Pearson A.; Chen S.; Boyer D.; Ruiz-Moreno J.; Garretson B.; Gupta A.; Hariprasad S.M.; Bailey C.; Reichel E.; Soubrane G.; Kapik B.; Billman K.; Kane F.E.; Green K.; Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012,119(10),2125-2132","journal-title":"Ophthalmology"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.ophtha.2009.11.024","volume":"117","author":"Campochiaro P.A.","year":"2010","unstructured":"Campochiaro P.A.; Hafiz G.; Shah S.M.; Bloom S.; Brown D.M.; Busquets M.; Sustained ocular delivery of fluocinolone acetonide by an intravitreal insert Ophthalmology 2010,117(7),1393-9","journal-title":"Ophthalmology"},{"key":"ref=144","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1517\/17425247.5.9.1039","volume":"5","author":"Kane F.E.","year":"2008","unstructured":"Kane F.E.; Burdan J.; Cutino A.; Green K.E.; Iluvien: a new sustained delivery technology for posterior eye disease Expert Opin Drug Deliv 2008,5(9),1039-46","journal-title":"Expert Opin Drug Deliv"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"347","DOI":"10.2174\/138920111794480651","volume":"12","author":"Schwartz S.G.","year":"2011","unstructured":"Schwartz S.G.; Flynn H.W.; Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011,12(3),347-351","journal-title":"Curr Pharm Biotechnol"},{"key":"ref=146","first-page":"435","volume":"Vol. 1","author":"Kompella U.B.","year":"2010","unstructured":"Kompella U.B.; Kadam R.S.; Lee V.H.L.; Recent advances in ophthalmic drug delivery 2010,Vol. 1,435-456","journal-title":"Recent advances in ophthalmic drug delivery"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S0002-9394(01)01010-8","volume":"132","author":"Jonas J.B.","year":"2001","unstructured":"Jonas J.B.; S\u00f6fker A.; Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001,132(3),425-427","journal-title":"Am J Ophthalmol"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1097\/IAE.0b013e318188c6e2","volume":"29","author":"Dyer D.","year":"2009","unstructured":"Dyer D.; Callanan D.; Bochow T.; Abraham P.; Lambert H.M.; Lee S.Y.; Schneiderman T.; Potts S.L.; Walker T.M.; Clinical evaluation of the safety and efficacy of preservative-free triamcinolone (triesence [triamcinolone acetonide injectable suspension] 40 mg\/ml) for visualization during pars plana vitrectomy. Retina 2009,29(1),38-45","journal-title":"Retina"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.ophtha.2006.08.044","volume":"114","author":"Lang Y.","year":"2007","unstructured":"Lang Y.; Leibu R.; Shoham N.; Miller B.; Perlman I.; Evaluation of intravitreal kenalog toxicity in humans. Ophthalmology 2007,114(4),724-731","journal-title":"Ophthalmology"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1167\/iovs.14-14188","volume":"55","author":"Sonoda S.","year":"2014","unstructured":"Sonoda S.; Sakamoto T.; Yamashita T.; Otsuka H.; Shirasawa M.; Kakiuchi N.; Uchino E.; Terasaki H.; Kawano H.; Effect of intravitreal triamcinolone acetonide or bevacizumab on choroidal thickness in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2014,55(6),3979-3985","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1001\/archopht.124.5.643","volume":"124","author":"Bandello F.","year":"2006","unstructured":"Bandello F.; Polito A.; Pognuz D.R.; Monaco P.; Dimastrogiovanni A.; Paissios J.; Triamcinolone as adjunctive treatment to laser panretinal photocoagulation for proliferative diabetic retinopathy Arch Ophthalmol 2006,124(5),643-50","journal-title":"Arch Ophthalmol"},{"key":"ref=152","first-page":"199","volume":"Vol. 11","author":"Kohly R.P.","year":"2010","unstructured":"Kohly R.P.; Muni R.H.; Kertes P.J.; Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular EDEMA 2010,Vol. 11,199-201","journal-title":"Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular EDEMA"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0161-6420(02)01969-3","volume":"110","author":"Beer P.M.","year":"2003","unstructured":"Beer P.M.; Bakri S.J.; Singh R.J.; Liu W.; Peters G.B.; Miller M.; Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection. Ophthalmology 2003,110(4),681-686","journal-title":"Ophthalmology"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1016\/j.ophtha.2007.11.012","author":"Feldman-Billard S.","year":"2008","unstructured":"Feldman-Billard S.; Chibani A.; H\u00e9ron E.; Vol 115, Ophthalmology 2008,917-917","journal-title":"Vol 115, Ophthalmology"},{"key":"ref=155","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S0886-3350(01)00783-0","volume":"27","author":"Fukushima H.","year":"2001","unstructured":"Fukushima H.; Kato S.; Kaiya T.; Yuguchi T.; Ohara K.; Noma H.; Effect of subconjunctival steroid injection on intraocular inflammation and blood glucose level after cataract surgery in diabetic patients J Cataract Refract Surg 2001,27(9),1386-91","journal-title":"J Cataract Refract Surg"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","volume":"119","author":"Do D.V.","year":"2012","unstructured":"Do D.V.; Nguyen Q.D.; Boyer D.; Schmidt-Erfurth U.; Brown D.M.; Vitti R.; One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology [Internet] 2012 Aug [cited 2020 Feb 20];119(8):1658\u201365 2012,119(8),1658-65","journal-title":"Ophthalmology [Internet] 2012 Aug [cited 2020 Feb 20];119(8):1658\u201365"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.ajo.2013.04.026","volume":"156","author":"Nepomuceno A.B.","year":"2013","unstructured":"Nepomuceno A.B.; Takaki E.; Paes de Almeida F.P.; Peroni R.; Cardillo J.A.; Siqueira R.C.; A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema Am J Ophthalmol 2013,156(3),502-510","journal-title":"Am J Ophthalmol"},{"key":"ref=158","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1097\/IAE.0b013e318285c99d","volume":"33","author":"Solaiman K.A.M.","year":"2013","unstructured":"Solaiman K.A.M.; Diab M.M.; Dabour S.A.; Repeated intravitreal bevacizumab injection with and without macular grid photocoagulation for treatment of diffuse diabetic macular edema Retina 2013,33(8),1623-9","journal-title":"Retina"},{"key":"ref=159","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1136\/bjophthalmol-2015-307136","volume":"100","author":"Heng L.Z.","year":"2016","unstructured":"Heng L.Z.; Sivaprasad S.; Crosby-Nwaobi R.; Saihan Z.; Karampelas M.; Bunce C.; Peto T.; Hykin P.G.; A prospective randomised controlled clinical trial comparing a combination of repeated intravitreal Ozurdex and macular laser therapy versus macular laser only in centre-involving diabetic macular oedema (OZLASE study). Br J Ophthalmol 2016,100(6),802-807","journal-title":"Br J Ophthalmol"},{"key":"ref=160","volume":"2","author":"Lundh A.","year":"2017","unstructured":"Lundh A.; Lexchin J.; Mintzes B.; Schroll J.B.; Bero L.; Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017,2(2)","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=161","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3233\/JRS-2012-0574","volume":"24","author":"Lexchin J.","year":"2012","unstructured":"Lexchin J.; Sponsorship bias in clinical research. Int J Risk Saf Med 2012,24(4),233-242","journal-title":"Int J Risk Saf Med"},{"key":"ref=162","doi-asserted-by":"publisher","first-page":"g5741","DOI":"10.1136\/bmj.g5741","volume":"349","author":"Naci H.","year":"2014","unstructured":"Naci H.; Dias S.; Ades A.E.; Industry sponsorship bias in research findings: a network meta-analysis of LDL cholesterol reduction in randomised trials of statins. BMJ 2014,349,g5741","journal-title":"BMJ"},{"key":"ref=163","unstructured":"Study of PAN-90806 Eye Drops, Suspension for Neovascular AMD"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/185519","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185519\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/185519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T04:24:40Z","timestamp":1723523080000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185519\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,12]]},"references-count":163,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,3,12]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886315666200902154322","relation":{},"ISSN":["1574-8863"],"issn-type":[{"type":"print","value":"1574-8863"}],"subject":[],"published":{"date-parts":[[2021,3,12]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-22","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}